NASDAQ:QNRX

Quoin Pharmaceuticals Q2 2026 Earnings Results & Report

Quoin Pharmaceuticals logo
$3.56 +0.20 (+5.95%)
Closing price 04:00 PM Eastern
Extended Trading
$3.63 +0.07 (+1.94%)
As of 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Quoin Pharmaceuticals missed analyst earnings expectations in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$1.90 versus the -$1.61 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
9:30 AM ET

Quoin Pharmaceuticals EPS Results

Actual EPS
-$1.90
Consensus EPS
-$1.61
Beat/Miss
Missed by -$0.29
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Quoin Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quoin Pharmaceuticals Q2 2026 Earnings FAQ

Quoin Pharmaceuticals (NASDAQ:QNRX) reported earnings of -$1.90 per share for Q2 2026, missing the consensus estimate of -$1.61. The report was announced on Friday, August 14, 2026.

Quoin Pharmaceuticals Earnings Headlines

Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Rating Lowered by Wall Street Zen
Beyond NVDA: The World’s Next #1 Company?
This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.tc pixel
See More Quoin Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quoin Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quoin Pharmaceuticals and other key companies, straight to your email.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals (NASDAQ:QNRX) is a clinical-stage pharmaceutical company focused on developing treatments for rare and orphan diseases, with an emphasis on conditions affecting the skin.

Its lead investigational product, QRX003, is a topical therapy being developed for Netherton syndrome, a rare genetic skin disorder. The company has also described plans to explore the treatment’s potential in other skin conditions. QRX003 is investigational and has not been established as a proven treatment.

View Quoin Pharmaceuticals Profile